Early use of beta-blockers attenuates systemic inflammatory response and lung oxygenation impairment after distal type acute aortic dissection

Heart and Vessels

Volumn 23, Issue 5, 2008, Pages 334-340

  Jo, Yusuke ^a   Anzai, Toshihisa ^a   Sugano, Yasuo ^a   Naito, Kotaro ^a   Ueno, Koji ^a   Kohno, Takashi ^a   Yoshikawa, Tsutomu ^a   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute aortic dissection; Beta blocker; C reactive protein; Inflammation; Lung oxygenation impairment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AROTINOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NITRITE;

ACUTE DISEASE; ADULT; AGED; AORTA DISSECTION; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD GAS ANALYSIS; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EARLY INTERVENTION; FEMALE; HUMAN; LEUKOCYTE COUNT; LUNG DISEASE; LUNG OXYGENATION IMPAIRMENT; MALE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANEURYSM, DISSECTING; AORTIC ANEURYSM; BLOOD GAS ANALYSIS; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 53149113808     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-008-1048-7     Document Type: Article

References (34)

1. Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, Evangelista A, Fattori R, Suzuki T, Oh JK, Moore AG, Malouf JF, Pape LA, Gaca C, Sechtem U, Lenferink S, Deutsch HJ, Diedrichs H, Marcos y Robles J, Llovet A, Gilon D, Das SK, Armstrong WF, Deeb GM, Eagle KA (2000) The International Registry of Acute Aortic Dissection (IRAD): New insights into an old disease. JAMA 283:897-903
2. Suzuki T, Mehta RH, Ince H, Nagai R, Sakomura Y, Weber F, Sumiyoshi T, Bossone E, Trimarchi S, Cooper JV, Smith DE, Isselbacher EM, Eagle KA, Nienaber CA (2003) Clinical profiles and outcomes of acute type B aortic dissection in the current era: Lessons from the International Registry of Aortic Dissection (IRAD). Circulation 108 Suppl 1:II312-II317
3. Komukai K, Shibata T, Mochizuki S (2005) C-reactive protein is related to impaired oxygenation in patients with acute aortic dissection. Int Heart J 46:795-799
4. Sugano Y, Anzai T, Yoshikawa T, Satoh T, Iwanaga S, Hayashi T, Maekawa Y, Shimizu H, Yozu R, Ogawa S (2005) Serum Creactive protein elevation predicts poor clinical outcome in patients with distal type acute aortic dissection: Association with the occurrence of oxygenation impairment. Int J Cardiol 102: 39-45
5. Hasegawa Y, Ishikawa S, Ohtaki A, Otani Y, Takahashi T, Sato Y, Koyano T, Yamagishi T, Ohki S, Kanda T, Morishita Y (1999) Impaired lung oxygenation in acute aortic dissection. J Cardiovasc Surg (Torino) 40:191-195
6. Anzai T, Yoshikawa T, Takahashi T, Maekawa Y, Okabe T, Asakura Y, Satoh T, Mitamura H, Ogawa S (2003) Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 99:47-53
7. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL (2000) beta-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101:2103-2109
8. Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H (2005) Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol 103:182-186
9. Song G, Hennessy M, Zhao YL, Li Q, Han WD, Qi Y, Zhao WN, Silke B, Barry M, Doyle R, Spiers JP (2006) Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). Pharmacol Res 54:57-64
10. Wikstrand J, Berglund G, Hedblad B, Hulthe J (2003) Antiathero-sclerotic effects of beta-blockers. Am J Cardiol 91:25H-29H
11. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T (2006) Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol 48:862-869
12. DeBakey ME, McCollum CH, Crawford ES, Morris GC, Jr., Howell J, Noon GP, Lawrie G (1982) Dissection and dissecting aneurysms of the aorta: twenty-year follow-up of five hundred twenty-seven patients treated surgically. Surgery 92:1118-1134
13. Schillinger M, Domanovits H, Bayegan K, Holzenbein T, Grabenwoger M, Thoenissen J, Roggla M, Mullner M (2002) C-reactive protein and mortality in patients with acute aortic disease. Intensive Care Med 28:740-745
14. Ishii T, Asuwa N (2000) Collagen and elastin degradation by matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in aortic dissection. Hum Pathol 31:640-646
15. Muller BT, Modlich O, Prisack HB, Bojar H, Schipke JD, Goecke T, Feindt P, Petzold T, Gams E, Muller W, Hort W, Sandmann W (2002) Gene expression profiles in the acutely dissected human aorta. Eur J Vasc Endovasc Surg 24:356-364
16. Sakuta A, Kimura F, Aoka Y, Aomi S, Hagiwara N, Kasanuki H (2007) Delayed enhancement on computed tomography in abdominal aortic aneurysm wall. Heart Vessels 22:79-87
17. Pararajasingam R, Nicholson ML, Bell PR, Sayers RD (1999) Noncardiogenic pulmonary oedema in vascular surgery. Eur J Vasc Endovasc Surg 17:93-105
18. Furusawa T, Tsukioka K, Fukui D, Sakaguchi M, Seto T, Terasaki T, Wada Y, Amano J (2006) The effects of a neutrophil elastase inhibitor on the postoperative respiratory failure of acute aortic dissection. Thorac Cardiovasc Surg 54:404-407
19. Munakata M, Itaya H, Daitoku K, Ono Y (2005) Remarkable improvement of hemodynamics by continuous hemodiafiltration in patients after operation for thoracic aortic dissection. Ann Thorac Cardiovasc Surg 11:277-280
20. Takahashi T, Anzai T, Yoshikawa T, Maekawa Y, Asakura Y, Satoh T, Mitamura H, Ogawa S (2003) Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction - role of neurohormones and cytokines. Int J Cardiol 88: 257-265
21. Murray DR, Prabhu SD, Chandrasekar B (2000) Circulation 101: 2338-2341
22. Bürger A, Benicke M, Deten A, Zimmer HG (2001) Am J Physiol Heart Circ Physiol 281:H14-H21
23. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo Cascio V, Cominacini L (2005) Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 23:589-596
24. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846
25. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T (2003) Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: A novel mechanism for antihypertensive action. Circulation 107:2747-2752
26. Ruffolo RR Jr, Feuerstein GZ (1997) Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 11Suppl 1: 247-256
27. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ (1995) Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 294:585-591
28. Feuerstein GZ, Fisher M, Nunnart J, Ruffolo RR Jr (1997) Carvedilol inhibits aortic lipid deposition in the hypercholesterolemic rat. Pharmacology 54:24-32
29. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF (1996) Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97:713-719
30. Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, Self C, Sinigaglia F (1997) Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 100:1513-1519
31. Severn A, Rapson NT, Hunter CA, Liew FY (1992) Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol 148:3441-3445
32. Viora M, Straface E, Di Genova G, Fattorossi A, Rivabene R, Camponeschi B, Masella R, Malorni W (1997) Oxidized low density lipoproteins impair peripheral blood mononuclear cell proliferation and cytokine production. Biochem Biophys Res Commun 232:359-363
33. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G (1992) Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263:92-98
34. Nishio R, Shioi T, Sasayama S, Matsumori A (2003) Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol 41:340-345